Xofigo® Is Indicated

for the treatment of patients with castration-resistant prostate cancer (CRPC),
symptomatic bone metastases and no known visceral metastatic disease.1

IMPORTANT DOSING UPDATE

Indication1

Xofigo® (radium Ra 223 dichloride) injection is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.

Important Safety Information

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. For important risk and use information about Xofigo, please see the full Prescribing Information.